<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONB-16007725</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-01-08</date_registration>
      <primary_sponsor>First Affiliated Hospital of Third Military Medical University</primary_sponsor>
      <public_title>Preliminary study of mesenchymal stem cells combined with platelet rich plasma injection for refractory tendinopathy</public_title>
      <acronym />
      <scientific_title>Preliminary study of mesenchymal stem cells combined with platelet rich plasma injection for refractory tendinopathy</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-01-01</date_enrolment>
      <type_enrolment />
      <target_size>Intervention Group:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=13043</url>
      <study_type>Observational study</study_type>
      <study_design>Before-After control</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Refractory tendinopathy</hc_freetext>
      <i_freetext>Intervention Group:mesenchymal stem cells combined with platelet rich plasma injection;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Tang Kanglai</firstname>
        <middlename />
        <lastname />
        <address>29 Gaotanyan, Shapingba District, Chongqing, China</address>
        <city />
        <country1 />
        <zip>400038</zip>
        <telephone>+86 13983681188</telephone>
        <email>tangkanglai@hotmail.com</email>
        <affiliation>First Affiliated Hospital of Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Tang Kanglai</firstname>
        <middlename />
        <lastname />
        <address>29 Gaotanyan, Shapingba District, Chongqing, China</address>
        <city />
        <country1 />
        <zip>400038</zip>
        <telephone>+86 13983681188</telephone>
        <email>tangkanglai@hotmail.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>(1) Age 18-45 years (18 yr and 45 yr included), male or female;
(2) Diagnosed tendinopathy refer to "military training injury diagnostic criteria" and no obvious symptom relief in 3 months after rest and administration of oral non-steroidal anti-inflammatory drugs, topical hormone therapy;
(3) Normal heart, lung, liver, kidney function
(4) Normal blood coagulation;
(5) Unwilling to receive surgery;
(6) Agreed to sign the informed consent;
(7) Compliance to follow-up process.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>45</agemax>
      <gender>Both</gender>
      <exclusion_criteria>(1) Patients of age that does not meet inclusion criteria;
(2) Fertility plan within 6 month and pregnancy or breast-feeding women;
(3) Non-Indications for MRI Examination;
(4) With diseases those could affect the result of the trial.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>UCLA shoulder score;Mayo elbow performance score;AOFAS ankle - hindfoot score;Adverse effects;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>PLA Fund 13CXZ008</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-01-19</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>